Igor Tsaur, Director and Chairman, Department of Urology at University Hospital Tübingen, shared a post on LinkedIn:
“Exciting News in Oncology Research!
I am very happy to share our latest publication investigating new therapeutic horizons for advanced penile cancer.
Our study highlights the promising role of B7-H3 (CD276) as a target for bispecific T-cell engager (BiTE) therapy, specifically utilizing constructs like CC-3. Given the limited treatment options for this rare disease, these findings represent a significant step toward more effective, targeted immunotherapy.
This project is particularly special to me: Helmut Salih and I jointly developed the initial idea to explore B7-H3 and CC-3 in penile cancer over a cup of coffee in his office two years ago.
Dear Helmut: It is incredibly rewarding to see that early vision yield such promising results today!
A huge congratulations and special thanks to Aleksander Kielbik for his consistent and resilient efforts in driving this research forward and for his unwavering dedication to improving outcomes for patients.”
Title: B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer
Authors: Kielbik A, Bahlinger V, Schürch CM, Barcena ML, Vakhrusheva O, Thomas A, Tsaur I, Heitmann JS, Salih HR, Hagelstein I.
Other articles featuring Igor Tsaur on OncoDaily.